Abstract Details

Title Superior test-retest reliability of cognitive assessment with Cognivue® vs SLUMS during an 18-month longitudinal study

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P7 - Poster Session 7 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-004

Objective Assess the test-retest reliability of the Cognivue cognitive assessment method vs SLUMS during an 18-month longitudinal study.

Background

Cognivue is an FDA-cleared computerized testing tool designed to assess cognitive impairment. In an FDA clearance study, Cognivue demonstrated good agreement with St. Louis University Mental Status (SLUMS) and other neuropsychological tests, and superior test re-test reliability compared to SLUMS across 2 sessions, 1 to 2 weeks apart (Cognivue regression fit: R²= 0.81, r= 0.90); SLUMS regression fit: R² = 0.67, r= 0.82).

Design/Methods

238 subjects from the FDA clearance study enrolled in the longitudinal study. They underwent Cognivue test and SLUMS at 3 sessions over 18 months (6, 12, 18 months post-FDA study). An analysis of rank linear regression test-retest reliability was performed for both tests. In a separate sub-analysis, subjects’ medical records were analyzed to determine the correlation between comorbidities or medication usage and Cognivue score.

Results

Among these 238 patients, Cognivue demonstrated similar linear regression scores across comparisons (test session [TS] 1&2: regression fit: R²= 0.76; r = 0.87; TS 1&3: regression fit: R²= 0.72; r = 0.85; TS 1&4: regression fit: R²= 0.73; r = 0.86). The SLUMS test demonstrated greater variability in regression scores across TS (TS 1&2: regression fit: R²= 0.63; r = 0.79; TS 1&3: regression fit: R²= 0.43 r = 0.65; TS 1&4: regression fit: R²= 0.64; r = 0.80).

Medical records of 203 subjects were analyzed. Overall, an increased co-morbidity count significantly decreased subjects’ Cognivue scores (correlation -0.21; P=0.01). Cardiopulmonary comorbidities had the largest impact on a patient’s Cognivue score (78.0 score for those without this comorbidity vs 67.1 score for those with; P<0.001).

Conclusions

Cognivue demonstrated superior test re-test reliability compared to SLUMS over 18 months after the FDA clearance study. An increased comorbidity count and cardiopulmonary comorbidities significantly decreased a subject’s Cognivue score over time.

Authors/Disclosures
John C. Andrefsky, MD (University Hospitals Parma) PRESENTER	No disclosure on file
	No disclosure on file
Reina Benabou, MD, PhD	No disclosure on file

��ɫ��

��ɫ��